Emerging echinocandins for treatment of invasive fungal infections (Q36458402)

14 August 2017

1 reference

title

Emerging echinocandins for treatment of invasive fungal infections (English)

1 reference

invasive fungal infections

14 August 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

84073

1 reference

3

John R Perfect

1 reference

14 August 2017

Michelle S Turner

1

1 reference

PubMed ID

16634699

14 August 2017

Richard H Drew

series ordinal

2

1 reference

PubMed ID

16634699

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

1 reference

14 August 2017

11

1 reference

14 August 2017

231-250

1 reference

14 August 2017

2

1 reference

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Invasive mold infections in allogeneic bone marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Advances and challenges in management of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Laboratory diagnosis of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Clinical pharmacology of antifungal compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Amphotericin B-induced nephrotoxicity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin activity against clinical isolates of fluconazole-resistant Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Studies of the paradoxical effect of caspofungin at high drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin: a review of its use in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin in combination with amphotericin B against Candida glabrata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activity of caspofungin against Candida albicans biofilms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy of micafungin for the treatment of candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Efficacy of micafungin alone or in combination against systemic murine aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Eradication of Invasive Mucormycosis--Effectiveness of the Echinocandin FK463

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Oral azole drugs as systemic antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

Susceptibility of clinical isolates of Fusarium to antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.2.231

10.1517/14728214.11.2.231

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16634699